Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 11

1.

O6-methylguanine-DNA methyltransferase regulation by p53 in astrocytic cells.

Blough MD, Zlatescu MC, Cairncross JG.

Cancer Res. 2007 Jan 15;67(2):580-4.

2.

Imaging correlates of molecular signatures in oligodendrogliomas.

Megyesi JF, Kachur E, Lee DH, Zlatescu MC, Betensky RA, Forsyth PA, Okada Y, Sasaki H, Mizoguchi M, Louis DN, Cairncross JG.

Clin Cancer Res. 2004 Jul 1;10(13):4303-6.

3.

Histopathological-molecular genetic correlations in referral pathologist-diagnosed low-grade "oligodendroglioma".

Sasaki H, Zlatescu MC, Betensky RA, Johnk LB, Cutone AN, Cairncross JG, Louis DN.

J Neuropathol Exp Neurol. 2002 Jan;61(1):58-63.

PMID:
11829344
4.

Tumor location and growth pattern correlate with genetic signature in oligodendroglial neoplasms.

Zlatescu MC, TehraniYazdi A, Sasaki H, Megyesi JF, Betensky RA, Louis DN, Cairncross JG.

Cancer Res. 2001 Sep 15;61(18):6713-5.

5.

PTEN is a target of chromosome 10q loss in anaplastic oligodendrogliomas and PTEN alterations are associated with poor prognosis.

Sasaki H, Zlatescu MC, Betensky RA, Ino Y, Cairncross JG, Louis DN.

Am J Pathol. 2001 Jul;159(1):359-67.

6.

Inactivation of p53 sensitizes U87MG glioma cells to 1,3-bis(2-chloroethyl)-1-nitrosourea.

Xu GW, Nutt CL, Zlatescu MC, Keeney M, Chin-Yee I, Cairncross JG.

Cancer Res. 2001 May 15;61(10):4155-9.

7.

Molecular subtypes of anaplastic oligodendroglioma: implications for patient management at diagnosis.

Ino Y, Betensky RA, Zlatescu MC, Sasaki H, Macdonald DR, Stemmer-Rachamimov AO, Ramsay DA, Cairncross JG, Louis DN.

Clin Cancer Res. 2001 Apr;7(4):839-45.

8.

Allelic loss of chromosome 1p and radiotherapy plus chemotherapy in patients with oligodendrogliomas.

Bauman GS, Ino Y, Ueki K, Zlatescu MC, Fisher BJ, Macdonald DR, Stitt L, Louis DN, Cairncross JG.

Int J Radiat Oncol Biol Phys. 2000 Oct 1;48(3):825-30.

PMID:
11020580
9.

Long survival and therapeutic responses in patients with histologically disparate high-grade gliomas demonstrating chromosome 1p loss.

Ino Y, Zlatescu MC, Sasaki H, Macdonald DR, Stemmer-Rachamimov AO, Jhung S, Ramsay DA, von Deimling A, Louis DN, Cairncross JG.

J Neurosurg. 2000 Jun;92(6):983-90.

PMID:
10839259
10.

The hPMS2 exon 5 mutation and malignant glioma. Case report.

Taylor MD, Perry J, Zlatescu MC, Stemmer-Rachamimov AO, Ang LC, Ino Y, Schwartz M, Becker LE, Louis DN, Cairncross JG.

J Neurosurg. 1999 May;90(5):946-50.

PMID:
10223463
11.

Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas.

Cairncross JG, Ueki K, Zlatescu MC, Lisle DK, Finkelstein DM, Hammond RR, Silver JS, Stark PC, Macdonald DR, Ino Y, Ramsay DA, Louis DN.

J Natl Cancer Inst. 1998 Oct 7;90(19):1473-9.

PMID:
9776413

Supplemental Content

Loading ...
Support Center